OFFICIAL RELEASE

Ash Access Technology, Inc. Appoints Carmine J. Durham Vice President of Sales, Marketing and Business Development

Former Bone Care International Executive Brings Highly Successful Pharmaceutical and Biotech Experience

Tuesday, August 9, 2005 3:50 PM EST - - - (Lafayette, Indiana) Ash Access Technology, Inc., an emerging leader in vascular access devices and the prevention of catheter-related bloodstream infections (CRBSI), announced today the appointment of Carmine J. Durham to the position of Vice President, Sales, Marketing and Business Development.

"We believe that Mr. Durham’s extensive experience in strategic marketing and product commercialization with leading pharmaceutical companies, (most recently Bone Care International, which was acquired by Genzyme Corporation in July of this year for over $600 million) is a distinct asset to our company," says Bob Truitt, President and CEO, Ash Access Technology, Inc. "As we bring our flagship product, AAT-023 (a novel antimicrobial / antithrombotic solution for the prevention of catheter-related bloodstream infection the eradication of biofilm), as well as our emerging vascular access devices to a global market, Mr. Durham's background will be invaluable. Not only do we have exceptional products working through our development pipeline, but we continue to build an exceptional team. We are excited to have a person with Carmine’s depth of experience and track record of success leading our market development activities.”

Most recently, Mr. Durham served as Vice President of Corporate Development and Strategy at Bone Care International where he played a key role in investor relations, corporate strategy and building value for the organization leading up to its recent merger with Genzyme. In prior roles, Mr. Durham was Vice President, Marketing at Bone Care, Business Unit Director at Abbott Laboratories, Director of Marketing at Knoll-BASF Pharma and held progressive sales and marketing leadership positions at Knoll-BASF Pharma, Boehringer Mannheim Corporation and Merck. Mr. Durham is a 1988 graduate of the University of New Mexico and has been active in a variety of biotech and medical professional organizations.

"I am very excited about the opportunity to join Ash Access Technology, particularly as we approach the pivotal clinical trial for AAT-023 in chronic kidney disease (CKD) patients on dialysis and finalize designs on our catheter-related technologies," said Carmine Durham. “With novel products like AAT-023, Ash Access is well positioned to become a leader in the emerging field of infection prevention by providing clinicians with innovative products designed to improve clinical outcomes and the quality of their patients lives.”

Ash Access Technology, Inc. is a privately-held company founded to develop antimicrobial and vascular access technologies, devices and methodologies to combat the deadly and expensive problem of catheter-related bloodstream infections (with an emphasis on prevention). Dr. Stephen R. Ash, Chairman and Director, Research and Development, is a practicing Nephrologist with the Arnett Clinic in Lafayette, Indiana, and is a world-recognized researcher and patent holder in extracorporeal devices, sorbent chemistry, and vascular and peritoneal access devices. Ash Access Technology is located in Lafayette, Indiana in the INOK Business Center.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control.